Mutations affecting the integrity of the essential torsin ATPase/cofactor system have been identified in a steadily increasing number of congenital disorders. Since most of these mutations affect brain function, much of the research has focused on deciphering disease etiology in the brain. However, torsin is expressed in a wide variety of nonneural tissues and is strictly conserved across species, including the lowest metazoans, suggesting that it plays roles extending beyond neurons. In this issue of the JCI, Shin et al. explored torsin function in the mammalian liver. The group reports major defects in hepatic lipid metabolism when the torsin system is compromised in mice. Remarkably, conditional deletion of either torsinA or its cofactor, lamina-associated polypeptide 1 (LAP1), resulted in fatty liver disease and steatohepatitis, likely from a secretion defect of VLDLs. This study considerably expands our understanding of torsin biology, while providing defined opportunities for future investigations of torsin function and dysfunction in human pathologies.
TorsinA and congenital disease
Torsins are proteins in the superfamily of ATPases associated with diverse cel lular activities (AAA + ) (1) . All four torsins en coded by the human genome local ize within the endoplasmic reticulum (ER) and nuclear envelope (NE) system. Despite being members of the AAA + ATPase superfamily, torsins are highly unusual ATPases. Perhaps their greatest departure from canonical AAA + proteins is their unique mechanism of ATPase activation. The torsin active site lacks critical elements and is therefore unable to hydrolyze ATP in isolation (2) . Instead, torsins rely on one of two transmem brane protein cofactors found within the ER/NE system to complement its active site (2, 3) . The first cofactor, locat ed within the inner nuclear membrane (INM), is laminaassociated polypeptide 1 (LAP1); the second is luminal domain-like LAP1 (LULL1), which remains in the peripheral ER (4) .
TorsinA was originally identified in a positional cloning approach to identify the genetic lesion underlying one of most common forms of childhoodonset dysto nia (DYT1 dystonia) (5) . Dystonias are a group of neurological disorders that often manifest as prolonged involuntary muscle contractions causing twisting movements. Although some forms of dystonia arise from injuries or drug exposure, many cases are genetic (1) . DYT1 dystonia is caused by a genetic lesion on chromosome 9, which deletes three base pairs of TOR1A, the gene that produces torsinA.
Patients with DYT1 dystonia are het erozygous for a TOR1A mutation that results in a single glutamate deletion (torsinAΔE) (5) , which interrupts cofactor stimulated ATPase activation of torsinA (2, 3) . Studies in several distinct model systems reported that manipulation of torsin or its cofactor compromises NE integrity and nuclear transport (6) (7) (8) . Since torsinAΔE fails to effectively rescue NEspecific phenotypes in torsinAknockout systems, this mutation likely represents torsinA loss of function (6, 8, 9) . Notably, lossof function mutations in LAP1 were recently identified in patients with neurological impairment and shortened lifespan, again underscoring the importance of the torsin LAP1 assembly in the NE (10).
Torsin redundancy and tissuespecific consequences
The torsinA DYT1-associated mutation specifically affects neural tissue because of the expression pattern and redun dancy. In humans, there are four torsin proteins, with torsinA and torsinB shar ing the most similarity. In mice, torsins share some functional redundancy at the NE (11), and torsinA and torsinB are expressed at similar levels in many non neural tissues including liver (12) . In adult and embryonic mouse neural tissue, torsinA is much more abundant than torsinB (12) . Consequently, if an organ ism acquires the torsinAΔE mutation, torsinB is not abundant enough to com pensate for any loss of function in neural tissue. Multiple studies suggest, however, that torsinB can accommodate the loss of torsinA in nonneural tissue (13) .
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The accumulation of lipids could result from disturbing any of the major processes in hepatic fatty acid (FA) metab olism, including the de novo synthesis of FAs, the generation of energy from FA oxidation, and the storage in LDs or secre tion via VLDLs of FAs. Shin et al. observed no defects in lipogenesis or FA oxidation in L-CKO mice. Thus, considering that L-CKO reduced circulating TGs, the reten tion of lipids seems likely to stem from a defect in VLDL secretion ( Figure 1A) . To investigate this, Shin et al. examined the secretion of a protein critical for VLDL biogenesis and integrity: apolipoprotein B100 (apoB100). The researchers used intranuclear lipid droplets (LDs), which also increased in both number and size within the cytosol. In A-CKO hepatocytes, intranuclear LDs were absent. Instead, the cytosol and ER appeared tightly packed with LDs. Despite this difference in LD distribution, both A-CKO and L-CKO mouse livers retained cholesterol and triglycerides (TGs). Concomitantly, the mice showed significantly lower circu lating cholesterol and TG levels ( Figure  1A) . Since A-CKO resulted in more severe phenotypes than did L-CKO, Shin et al. suggested that deletion of LAP1 in hepato cytes caused lipid retention by reducing torsinA activity at the INM (14) .
sequences of knocking out torsinA in hepatocytes are striking (14) .
Torsins and lipid metabolism
Shin et al. reported that the conditional deletion of torsinA (A-CKO) or LAP1 (L-CKO) in murine hepatocytes inter fered with VLDL assembly and secretion, resulting in profound lipid dysregulation (14) . The livers of A-CKO and L-CKO mice specifically exhibited excessive lipid retention ( Figure 1A) , a phenomenon that can lead to nonalcoholic fatty liver disease. The authors demonstrated that the nuclei of some hepatocytes from L-CKO mice are enlarged due to aberrantly localized While apoB100 is translated into the ER, MTP aids in apoB100 lipidation by extracting phospholipids (PLs) and TGs from the ER. In the absence of lipidation, apoB100 is degraded. TorsinA may facilitate unlipidated apoB100 degradation or cooperate with MTP to facilitate apoB100 lipidation. Alternatively, torsinA may be involved in coordinating the translocation, folding, and lipidation of apoB100. Once the VLDL precursor grows to an appropriate size within the ER, the mature VLDL travels to the Golgi. VLDLs are packaged into specialized vesicles that may require torsinA for their formation.
researchers selectively expressed torsin in the neurons or muscles of flies otherwise devoid of the protein. However, neural or muscular torsin expression failed to res cue the pupalstage lethality associated with torsin knockout (21) . Instead, torsin expression within the larval fat body, an organ with many functional similarities to the liver, was necessary to suppress the knockout phenotype. Moreover, a con nection between torsinA and lipid metab olism was recently proposed in a mouse model for primary dystonia (22) . Thus, the emerging role of the torsin system in lipid metabolism, stemming from studies in various model systems, is likely evolution arily conserved (14, 21, 22) .
The profound effect that Shin et al. observed upon LAP1 deletion raises a major question: How does losing torsinA activity at the INM interfere with VLDL biogenesis in the ER (20) ? NElocalized LAP1 may affect lipid secretion indirectly by influencing torsin localization or by shifting the equilibrium of oligomeric torsin species. Another possibility is that the NE plays a yetunknown role in the biogenesis of VLDL, which is consistent with our knowledge of diseases that affect lipid metabolism and are caused by muta tions in INM proteins (23, 24) . As outlined above, additional investigations will probe the testable hypotheses that were borne out by Shin et al., while also motivating a fresh look at lipid metabolism in patients with genetic lesions in LAP1 or torsinA. Concepts emerging from these future studies will enhance our understanding of torsin function and might provide import ant clues to further our understanding of torsinrelated pathologies. metabolic labeling to show that apoB100 was poorly secreted in both L-CKO and A-CKO mice (14) . Importantly, this defect was specific to apoB100, as general pro tein secretion remained unaffected.
Possible mechanisms and future directions
What part of the apoB100 and VLDL secretion process could involve torsinA? As apoB100 is translated into the ER the chaperone microsomal TG transfer pro tein (MTP) adds lipids to apoB100 to form an initial lipidpoor VLDL precursor (15) . If MTP fails to initiate lipidation, apoB100 undergoes proteasomal degradation (16) . Shin et al. reported that in L-CKO and A-CKO livers, newly synthesized apoB100 levels were strongly reduced (14) . Thus, torsinA could play a role in apoB100 lipi dation alongside MTP ( Figure 1B) . Nota bly, a truncated version of torsinA was recently shown to deform lipid vesicles in vitro, a property that might facilitate mobi lization of lipids from the lipid bilayer (17) .
Alternatively, torsinA could be impli cated in the coordination of apoB100 trans lation, folding, and degradation within the ER lumen ( Figure 1B) . Pulsechase or imagingbased experiments that monitor the levels and localization of apoB100, along with inhibitors of ERassociated deg radation machinery and the lysosomal path way, could yield additional insight. It would also be interesting to test whether torsinA interacts with apoB100 during VLDL bio genesis in a manner that depends on lipid availability. Furthermore, whether LAP1 modulates the potential apoB100-VLDL interaction by controlling torsinA ATPase activity and oligomeric state would be exciting to investigate (18, 19) .
Finally, torsinA could function during VLDL vesicular transport ( Figure 1B) . VLDLs are trafficked in vesicles unique from those that traffic bulk secreted pro teins (20) . If these specialized vesicles require torsinA for maturation, general protein secretion would appear normal, consistent with the Shin et al. findings (14) .
In addition to the study by Shin et al., other recent work supports a potential role for torsin in lipid metabolism. Data from Grillet et al. suggest that the single torsin homolog in Drosophila melanogaster plays a critical role in promoting membrane pro liferation during fly development (21) . The
